Is NCT06904911 recruiting in Philadelphia, PA?

Yes, NCT06904911 is currently recruiting participants at its Philadelphia, PA location. This acute ischemic stroke from large vessel occlusion clinical trial is actively enrolling qualified participants.

Is participation in this Philadelphia clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Acute Ischemic Stroke From Large Vessel Occlusion Clinical Trial in Philadelphia, PA

Q: How do I join the acute ischemic stroke from large vessel occlusion clinical trial in Philadelphia?

To join this clinical trial in Philadelphia, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Acute Ischemic Stroke From Large Vessel Occlusion Study in Philadelphia

This is a prospective, single-arm, open-label study to evaluate the efficacy of intra-arterial tenecteplase in improving microvascular reperfusion following successful large vessel recanalization. Acute ischemic stroke patients with large anterior circulation large vessel occlusion will receive a single weight-based dose of intra-arterial tenecteplase after achieving successful large vessel recanalization (defined as TICI ≥ 2b) via standard of care mechanical thrombectomy. Microvascular flow will be assessed by quantitative angiography before and after the intra-arterial drug administration in order to quantify the impact of targeted thrombolysis on microvascular reperfusion. Reperfusion will be secondarily assessed with 24-hour imaging, final infarct volume will be quantified 72 hours following treatment, and functional outcome will be assessed in the short-term by the NIHSS and in the long-term by the 90-day modified Rankin Scale.

Sponsor: University of Pennsylvania

Who Can Participate

Inclusion Criteria

Patient/legally authorized representative has signed the Informed Consent Form

At least 18 years of age

Ability to comply with the study protocol, in the investigator's judgment

Acute ischemic stroke attributed to anterior circulation large vessel occlusion (of the internal carotid artery or first segment of the middle cerebral artery based on CTA, MRA, or catheter angiogram) being treated with mechanical thrombectomy

NIHSS ≥ 6 at the initiation of endovascular therapy (arterial puncture)

Time from stroke onset to IA-TNK administration \< 24 hours. Stroke onset is defined as the time the patient was last known to be at their neurologic baseline

ASPECTS ≥ 6 on pre-MT CT imaging

If treated \> 6 hours from stroke onset, CTP imaging must demonstrates favorable mismatch profile (based on RAPID processing: infarct core \<70 mL, mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 mL)

Qualifying neuroimaging (CT and CTP, if applicable) must be obtained \<120 minutes prior to arterial puncture.

Exclusion Criteria

Current participation in another investigational drug or device study

Known hypersensitivity or allergy to any ingredients of tenecteplase

Active internal bleeding

Known bleeding diathesis (Alzheimer's patients taking lecanemab)

Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \> 1.7

Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)

Treatment with a thrombolytic within the last 3 months prior to randomization, inclusive of intravenous thrombolysis during the index stroke.

Baseline platelet count \< 100,000/microliter (results must be available prior to treatment)

Baseline blood glucose \> 400 mg/dL (22.20 mmol/L)

Baseline blood glucose \< 50 mg/dL needs to be normalized prior to randomization

Intracranial or intraspinal surgery or trauma within 2 months

Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months

History of acute ischemic stroke in the last 90 days

History of hemorrhagic stroke

Presumed septic embolus; suspicion of bacterial endocarditis

Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed

Systolic BP \>185 mmHg or diastolic BP \>110 mmHg, refractory to treatment

Suspicion of aortic dissection

Known allergy to iodine or iodinated contrast

Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram

Renal failure as defined by a serum creatinine \> 3.0 mg/dl or GFR \< 30

Known intracranial neoplasm

GI bleeding within the past 21 days

Pre-existing medical or neurological disease that will confound the neurological or functional evaluations

Premorbid (prior to the index stroke) modified Rankin Scale (mRS) score ≥ 3 Additional neuroimaging exclusion criteria:

ASPECTS \<6 on pre-MT CT imaging

Acute intracranial hemorrhage or contrast extravasation on CT before or immediately after MT (prior to study drug administration)

Significant mass effect with midline shift on non-contrast CT before or immediately after MT

Cervical or intracranial stent placement during endovascular therapy

Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA, MRA, or catheter angiography

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06904911) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Ischemic Stroke From Large Vessel Occlusion Treatment Options in Philadelphia, PA

If you're searching for acute ischemic stroke from large vessel occlusion treatment options in Philadelphia, PA, this clinical trial (NCT06904911) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute ischemic stroke from large vessel occlusion specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute ischemic stroke from large vessel occlusion clinical trials near you to find additional studies recruiting in your area.

Acute Ischemic Stroke From Large Vessel Occlusion Clinical Trial in Philadelphia, PA

Expert Care in Philadelphia

IRB Approved

No-Cost Care

Apply for This Philadelphia Location

Why Participate?

Simple Process